As shown inFig. from the ascites of malignant mesothelioma patients. Mesothelioma cells grown as monolayers or as spheroids expressed comparable levels of mesothelin; however, spheroids were at least 100 times less affected by SS1P. To understand this disparity in cytotoxicity, we made fluorescence-labeled SS1P molecules and used confocal microscopy to examine the time course of SS1P penetration within spheroids. The penetration was limited after 4 hours. Interestingly, we found a significant increase in the number of tight junctions in the core area of spheroids by electron microscopy. Expression of E-Cadherin, a protein involved in the assembly and sealing of tight junctions and highly expressed in malignant mesothelioma, was found significantly increased in spheroids as compared to monolayers. Moreover, we found that siRNA silencing and antibody inhibition targeting E-Cadherin could enhance SS1P immunotoxin therapyin vitro. == Conclusion/Significance == This work is one of the first to investigate immunotoxins in 3D tumor spheroidsin vitro. This initial description of anin vitrotumor model may offer a simple and more representative model ofin vivotumors and will allow for further investigations of the microenvironmental effects on drug penetration and tumor cell killing. We believe that the methods developed here may apply to the studies of other tumor-targeting antibodies and immunoconjugatesin vitro. == Introduction == Solid tumors remain a major problem despite a vast number of anti-cancer brokers available. Advances in antibody-based therapies represent a promising new approach to treating solid cancer, yet a major challenge involves delivering sufficient amounts of antibodies and immunoconjugates within tumor masses[1]. For an anti-cancer antibody agent to be successful, it must satisfy two requirements: (a) the agent must be effective in the tumor microenvironment, and (b) the agent must reach the tumor cells in optimal quantities. Tumor microenvironments are difficult to studyin vivoand have been extensively studied primarily at the monolayer levelin vitro. Cancer cells cultured as monolayers exhibit less resistance to therapy than those grownin vivoand may be explained by multicellular resistance, a mechanism for drug resistance attributed to cell-cell contacts, cell-matrix contacts, and the three-dimensional (3D) shape found in tissue[2][4]. Multicellular resistance acquired by tumor cells may contribute to difficulties in translating Dabrafenib (GSK2118436A) promising findings fromin vitrostudies into therapy[5].In vitromulticellular cancer spheroids, therefore, have begun to bridge the complexity gap between monolayer cell culture andin vivotumors and have become valuable models in the study of drug resistance[6]. Mesothelioma is a fatal cancer of the mesothelium and predominantly forms from previous exposure to asbestos[7]. Malignant mesothelioma (MM) is often resistant to chemotherapy[8]and radiation[9]. Prognosis is usually poor and average survival ranges from a few months to less than 2 years[10]. To investigate apoptotic resistance in mesothelioma, Broaddus and colleagues recently reported Dabrafenib (GSK2118436A) that mesothelioma cells acquired resistance when formed Dabrafenib (GSK2118436A) into 3D spheroidsin vitro[11]. These spheroids exhibited many features of the tumor microenvironment, modeling the avascular region of tumors that is dependent on diffusion. Antibody-based therapy has emerged as a new promising strategy to treat mesothelioma and other solid tumors[12]. However, tumor microenvironments that present significant barriers to penetration by antibodies and immunoconjugates have been studied onlyin vivo. A simple, reliable, high-throughput and less expensivein vitrotumor model should be very useful for characterizing and screening antibodies and immunoconjugates for cancer therapy. Mesothelin is a tumor differentiation antigen that is normally expressed in low levels around the mesothelial cells lining the pleura, peritoneum and pericardium[12]. Mesothelin is usually highly expressed in mesothelioma, as well as ovarian cancer and lung cancer[12],[13], and has been shown to be a biomarker for the diagnosis of mesothelioma[14]. Although the biological function of mesothelin remains unclear, mesothelin’s limited expression in normal tissue and high expression in various cancers make it an attractive candidate for immunotherapy[12]. The mucin CA125/MUC16 is also highly expressed at the cell surface in mesothelioma and ovarian cancer[15]. The binding of mesothelin to CA125/MUC16 may play a role in Rabbit Polyclonal to COX5A the implantation and peritoneal spread of tumors by cell adhesion[15]. The recombinant immunotoxin SS1P is currently in clinical trials for mesothelioma. SS1P.